Gilead Sciences has made another foray into the natural killer (NK) cell category, paying $300 million upfront to access Dragonfly Therapeutics' TriNKET platform to find therapies for cancer and ...

Dragonfly has an ongoing phase 1/2 clinical trial of DF6002 for patients with advanced solid tumours, which began in July 2020 after the FDA granted clearance to begin clinical trials in May.

Crypto.com Onchain and Ledger are some of the best crypto wallets for 2025. Wallets give you control over your digital assets. Many, or all, of the products featured on this page are from our ...